Metanovas Biotech
The AI engine Fit Assessment
BetaMetanovas effectively leverages machine learning for drug discovery and repurposing, demonstrating a strong commitment to expanding therapeutic options.
Blurb
Metanovas develops drugs, dietary supplements, functional foods, and cosmetics using AI technology.
HQ Location
United States
Founded
2021
Employees
11 - 50
Total funding raised
$10.00M
Last Funding Event
Seed, $10.00M, March 31, 2022
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Repurposing
Provider of an AI-enabled drug and disease discovery platform. The company provides a drug and disease discovery platform empowered by machine learning and AI to discover novel disease targets, screen for potential drugs, repurpose existing drugs for new indication and optimization ADMET property prediction, enabling a more efficient way to generate new insights and discover more effective medicines to decipher disease biology.